(upbeat music) >> Welcome back to Vegas, baby. Lisa Martin here with theCUBE. We are live at Caesar's Forum covering Snowflake Summit 22. This is day two of our wall to wall coverage on theCUBE you won't want to miss. We've got an exciting customer story to talk to you about next with Novartis and Snowflake. Please welcome two guests to theCUBE. Loïc Giraud, Global head digital delivery, Novartis. I hope I got the name right. >> Yes. Hi, thank you. >> I did my best. >> Absolutely. >> Lisa: (laughs) Jesse Cugliotta also joins us. Global Industry Lead, Healthcare and Life Sciences at Snowflake. Welcome with theCUBE, gentlemen. >> Thank you for having us. Good morning. >> So it was great to hear Novartis is a household word now, especially with what's gone on in the last two years. I had a chance to see the Keynote yesterday, heard Novartis mention in terms of a massive outcome that Snowflake is delivering that we're going to get to. But Loic talk to us about Novartis global 500 organization. You rank among the world's top companies investing in R&D, the massive portfolio and you're reaching nearly 800 million patients worldwide. That's huge, but there's been a lot of change in the healthcare and life sciences industry, especially recently. Talk to us about the industry landscape. What are you seeing? >> As you described, Novartis is one of the top life science company in the world. We are number three. We operate in 150 countries, and we have almost 120,000 employees. Our purpose is actually to reimagine medicine for the use of data science and technology and to extend people's life. And we really mean it. I think, as you mentioned, we treat eight or 9 million patient per year with our drugs. We expect to treat more than a billion patients in near time soon. Over the last few years, especially during COVID, our digital transformation help us to accelerate the drug discovery and then the commiseration of our drug to markets. As it was mentioned in the Keynote yesterday, we have actually been able to reduce our time to market. It used to take us up to 12 years and cost around 1.2 billion to discover and commercialize drug. And now we've actually use of technology like Snowflake, we have been able to reduce by two to three years, which ultimately is a benefit for our patients. >> Absolutely. Well, we're talking about life and death situations. Talk about... You mentioned Novartis wants to reimagine medicine. What does that look like? Where is data in that and how is Snowflake an enabler of reimagining medicine? >> So data is core for our asset, is a core of enterprise process. So if you look at our enterprise, we are using data from the research, for drug development, in manufacturing process, and how do we market and sell our product through HCPs and distribute it to reach our patients. If you build through our digital transformation we have created this integrated data ecosystem, where Snowflake is a core component. And through that ecosystem, we are able to identify compounds and cohorts, perform clinical trials, and engage HCPs and HGOs so that can prescribe drugs to serve our patient needs. >> Jesse, let's bring you into the conversation. Snowflake recently launched its healthcare and life sciences data cloud. I believe that was back in March. >> It was. >> Just a couple of months ago. Talk to us about the vertical focus. Talk to us about what this healthcare and life sciences data cloud is aiming to help customers like Novartis achieve. >> Well, as you mentioned there, Snowflake has made a real pivot to kind of focus on the various different industries that we serve in a new way. I think historically, we've been engaged in really, all of the industries across the major sectors where we participate today. But historically we've been often engaging with the office of IT. And there was a recognition as a company that we really need to be able to better speak the language of our customers in with our respective industries. So the entire organization has really made a pivot to start to build that capability internally. That's part of the team that I support here at Snowflake. And with respect to healthcare and life sciences, that means being able to solve some of the challenges that Loic was just speaking about. In particular, we're seeing the industry evolve in a number of ways. You bring up clinical research in the time that it takes to actually bring a drug to market. This is a big one that's really changed a lot over the last couple of years. Some of the reasons are obvious and other ones are somewhat opportunistic. When we looked at what it takes to get a drug to market, there's several stages of clinical research that have to be participated in, and this can often take years. What we saw in the last couple of years, is that all of a sudden, patients didn't want to physically participate in those anymore, because there was fear of potential infection and being in a healthcare facility. So the entire industry realized that it needed to change in terms of way that it would engage with patients in that context. And we're now seeing this concept of decentralized clinical research. And with that, becomes the need to potentially involve many different types of organizations beyond the traditional pharma, their research partners, but we're starting to see organizations like retail pharmacies, like big box retailers, who have either healthcare delivery or pharmaceutical arms actually get involved in the process. And of course, one of the core things that happens here is that everyone needs a better way to collaborate and share data amongst one another. So bringing this back to your original question, this concept of being able to do exactly that is core to the healthcare and the life sciences data cloud. To be able to collaborate and share data amongst those different types of organizations. >> Collaboration and data sharing. It seems to me to be a differentiator for Snowflake, in terms of being able to deliver secure, governed powerful analytics and data sharing to customers, partners to the ecosystem. You mentioned an example of the ecosystem there and how impactful to patients' lives, that collaboration and data sharing can be. >> That's absolutely right. It's something that if you think about all of the major challenges that the industry has had historically, whether it is high costs, whether it are health inequities, whether it is physicians practicing defensive medicine or repeat testing, what's core to each one of these things is kind of the inability to adequate collaborate and share data amongst all of the different players. So the industry has been waiting for the capability or some sort of solution to be able to do this, I think for a long, long time. And this is probably one of the most exciting parts of the conversations that we have with our customers, is when they realize that this is possible. And not only that it's possible within our platform, but that most of the organizations that they work with today are also Snowflake customers. So they realize that everyone's already here. It's just a matter of who else can we work with and how do we get started? >> Join the party. >> Exactly. >> Loic talk to us about Novartis's data journey. I know you guys have been, I believe using Snowflake since 2017 pre pandemic. But you had a largely on-premises infrastructure. Talk to us about the decision of Novartis to go to the cloud, do it securely and why you chose to partner with Snowflake. >> So when we started our journey in 2018, I think the ambition that our CEO, was to transform all enterprise processes for the use of digital tech. And at the core of this digital tech is data foundation. So we started with a large program called Formula One, which aim to integrate all our internal and external data asset into an integrated platform. And for that, I think we've built this multicloud and best upgrade platform, where Snowflake is a core component. And we've been able to integrate almost 1,000 data asset, internal and external for the platform to be able to accelerate the use of data to create insight for our users. In that transformation, we've realized that Snowflake could be a core component because of the scalability and the performance with large dataset. And moreover, when Snowflake started to actually open collaboration for their marketplace, we've been able to integrate new data set that are publicly available at the place that we could not do on ourself, on our own. So that is a core component of what we are trying to do. >> Yeah, and I think that's a great example of really what we're talking about here is that, he's mentioning that they're going out to our marketplace to be able to integrate data more easily with some of the vendors there. And that is kind of this concept of the healthcare and life sciences data cloud realized, where all of a sudden, acquiring and bringing data in and making it ready for analysis becomes much faster, much easier. We continually see more and more vendors coming to us saying, I get it now, I want in. Who else can I work with in this space? So I think that's a perfect example of how this starts to become real for folks. >> Well, it sounds like the marketplace has been an enabler, Loic, of the expansion of use cases. You've grown this beyond drug development. I read that you're developing new products and services for healthcare providers to personalize treatments for patients, which we all are demanding patients. We want that personalized care. But talk about the marketplace as a facilitator of those expanding use cases that Snowflake is powering. >> Yes. That's right. I mean we have currently almost 65 use cases in production and we are in advanced progress for over 200 use cases and they go across all our business sector. So if you look at drug development, we are monitoring our clinical trials using Snowflake. If you look at our omnichannel marketing, we are looking at personalization of information with our HCPs and HGOs using snowflake. If you look at our manufacturing process, we are looking at yet management, freight optimization, inventory, insight. So almost across all the industry sectors that we have, I think we are using the platforms to be able to deliver faster information to our users. >> And that's what we all want. Faster information. I think in the pandemic we learned that access to real time data in every industry wasn't a nice to have. That was a- >> Necessity. >> Absolute necessity. >> Yeah. >> And made the difference for companies that survived and thrived and those that didn't. That's something that we learned. But we also learned that the volume of data just continues to proliferate. Loic, you've been in the industry a couple of decades. What do you see? And you've got, obviously this great foundation now with Snowflake. You've got 65 use cases you said in production. What's the future of the data culture in healthcare and life sciences from your perspective? >> So my perspective. It is time now we give the access to our business technologies to be able to be self-sufficient using digital product. We need to consumerize digital technology so they can be self-sufficient. The amount of problems that we have to solve, and we can now solve with new technology has never been there. And I think where in the past, where in the next few years that you will see an accelerated generation of insight and an accelerated process of medicine by empowering the business technologies to use a technology that like Snowflake and over progress. >> What are your thoughts Loic, of some of the, obviously a lot of news coming out yesterday from Snowflake, we mentioned standing room only in the Keynote. This I believe is north of 10,000 attendees. People are ready to engage in person with Snowflake, but some of the news coming out, what is your perspective? You've been a partner of theirs for a while. What do you see from Snowflake in terms of the news, the volume of customers it's adding, all that good stuff? >> I must say I was blown away yesterday when Frank was talking about the ramp up of customers using Snowflake. But also, and I think in Benoit and Christian, and they talk about the innovation. When you look at native application or you look at hybrid tables, we saw a thing there. And the expansion of the marketplace by monetization application, that is something that is going to accelerate the expansion, not only on the company, but the integration and the utilization of customers. And to Jesse's point, I think that it is key that people collaborate using the platform. I think we want to collaborate with suppliers and providers and they want to collaborate with us. But we want to have a neutral environment where we can do that. And Snowflake can be that environment. >> And do it securely, right? Security is absolutely- >> Of course. I mean that's really table stake for this industry. And I think the point that you just made Loic, is very important, is that, the biggest question that we're often asked by our customers is who else is a customer within this industry that I can collaborate with? I think as Loic here will attest to, one of the challenges within life sciences in particular is that it is a highly regulated industry. It is a highly competitive industry, and folks are very sensitive about referenceability. So about things like logo usage. So to give some ideas here, people often have no idea that we're working with 28 of the top 50 global pharma today, working with seven of the top 12 global medical device companies today. The largest CROs, the largest distributors. So when I say that the party is here, they really are. And that's why we're so excited to have events like these, 'cause people can physically introduce themselves to one another and meet, and actually start to engage in some of these more collaborative discussions that they've been waiting for. >> Jesse, what's been some of the feedback that you've heard the last couple of days on the healthcare and life sciences data cloud? You've obviously finally gotten back to engaging with customers in person. But what are some of the things, feed on this street have said that you've thought, we made the absolute right decision on this pivot? >> Yeah, well I think some of it speaks to the the point I was just speaking about, is that they had no idea that so many of their peers were actually working with Snowflake already and that how mature their implementations have actually been. The other thing that folks are realizing is that, a lot of the technologies that serve this ecosystem, whether they're in the health tech space, whether they're clinical management or commercial engagement or supply chain planning technologies, those companies are also now pivoting to Snowflake, where they're either building a part or the entirety of their platform on top of ours. So it offers this great way to start to collaborate with the ecosystem through some of those capabilities that we spoke about. And that's driving new use cases in commercial, in supply chain, in pharmacovigilance, in clinical operations. >> Well, I think you just sum up beautifully why the theme of this conference is the world of data collaboration. >> Yes, absolutely. >> The potential there, that Snowflake is unleashing to the world is I think is what's captivating to me. That you just scratch on the surface about connecting and facilitating this collaboration and this data sharing in a secure way across industries. Loic, last question for you. Take us home with what is next for Novartis. You've done a tremendous amount of digitalization. 65 use cases in production with Snowflake. What's next for the company? >> See, I think that in next year's to come, open collaboration with the ecosystem, but also personalization. If you look at digital medicine and access to patient's informations, I think this is probably the next revolution that we are entering into. >> Excellent. And of course those demanding patients aren't going to want anything slower or less information. Guys, thank you for joining me on the program talking about the Novartis-Snowflake collaboration. The partnership, the outcomes that you're achieving and how this is really dramatically impacting the lives of hundreds of millions of people. We appreciate your time and your insights. >> Thank you for having us. This was fun. >> My pleasure. >> Thank you. >> For my guests, I'm Lisa Martin. You're watching theCUBE. This is live from Las Vegas, day two of our coverage of Snowflake Summit 22. I'll be right back with my next guest, so stick around. (upbeat music)

>>live from Las Vegas. It's the Q covering AWS executive. Something brought to you by extension. >>Welcome back, everyone to the cubes. Live coverage of the ex Censure Executive Summit here in AWS. Reinvent I'm your host, Rebecca Knight. We have three guests for this segment. We have Fang Deng. She is the big data and an Advanced Analytics program. Lead analytic Seo hee at Novartis. Thank you so much for coming on the show. Thank you. We have low eq zero. He is Novartis head of Analytic Seo Hee. Thanks so much. Look, and Vika sinned. Wan Hee hee is applied intelligence delivery lead at Accenture. Thank you so much. Thank you. So I want to start with you. Look, no. Novartis, of course, is a household name. It's one of the largest pharmaceutical companies in the world. But that left you to just walk our viewers a little bit through your business and sort of the pain points you were looking to solve with this journey Thio to the cloud >>you think you ever care? So I think if I if we look at the company, I think Wayne realized that it is more and more difficult to bring new trucks to market, so it takes about 12 years and on $1.2 billion to find a new trick. So at the same time, we see that there's more and more patient that need access to medicines. So in the last two years, I think we tried toe clear the new strategy where we're trying to re imagine medicine for user's data and technology. So in 2018 we've recruited a new studio that's came and I tried to build a digital ambition which is around fabulous, which is the innovation, the operation and the engagement on the innovation. What we're trying to do is to find new compound, will application off existing compounds into our business, make sure that I think patients can get access to drugs much faster and earlier on in the operation. We are trying to optimize the backbone off day to day processes, beat in the manufacturing or in the supply chain, or in the commercialization to ensure that the patient also get access to that much faster in the engagement. We're trying to healthy a cheapie and the players and then the and the patients to better understand the tracks reproduce as well as on the medication they need to have to receive treatment. So if you look at these three pillars, the cloud strategy is an essential portion of it. Because in all of its processes we have a lot of data and full cloud. I think we can make use off his data to help to innovate, open, right and engage. >>So as you as you said, it's really about reimagining medicine. I mean, from the drug discovery process to how it's helping patients live, live longer, healthier lives. Thanks. So talk about the vision for the Formula One platform. >>Yeah, aside, like a mission before we trying to re imagine our products for the patient. And we're trying to use more the more data history data and also the public data try to support our products. And the Formula One is our future enterprise data and the next perform for our new artists. So our objective is trying to love you all the new technology and also trying to consolidate over data in our Macleod and build up this platform for the whole notice Users support our business, do better products full patient. >>So when it comes to these these new new platforms, new technologies that are being introduced. We know that oftentimes the technology is the easy part. Or at least the more straightforward part I should say. But it's it's sort of getting people on board the change management. What are some of the challenges that you that you know of artists faced in terms of of the culture and the skills for your for your workforce? >>So if you look at that, the are in disgrace, very traditionally nature. And when we embarking the details confirmation, I think the first thing we had to change the culture of the company. So when you when you listen to our CEO, I think you tried to promote this invoice culture where all of us are Syrian leaders. And then we walk, you know, as a thing as an organization where we try to help each other and more and more collaborate when it comes to digital transformation. When we started this having this period, we've realised actually that workforce was not trained, so the first few things that we did disease is a tight wire new workforce, but also try to actually identify the advocate ambassadors. I could go and then go into residual confirmation early on to be able to help and to guide the office to get for that. So it's actually it's totally immaterial, Johnny. And then we are now in the second year and we've seen already a tremendous four guys, right? >>Can you describe some of the changes that you've seen him? I mean, I'm really interested in what you talk about. The ambassador's, the people who are going to spread the good word. What are what are some of the changes that you've seen in your workforce? Yeah, we can mention >>that. It's like you mentioned before. Um, like, talking about regarding overall catch a bus back to tried to leverage a new attack. Knowledge like the delivery perspective. We trying to do more automation, and the May 1 side is trying to get more efficiency and also another side. Try to ensure the intern responsibility for one product to be produced and also at the same time, let me through more automation to think about this secret inside the compound inside. Help us a lot of in pulling that part also, because >>maybe I can compliment that so I think if you look at it when the initial studying part of our journey, I think that a lot of people were reluctant to go and then tie to work on a cloud and to work with digital technology. So we found few projects where we felt there's a good ready for money. And as we can deliver fast in fact, Andi to things like, I don't get reviewed t piece every. Make sure that when we went, our field falls, go then and talk to the hippies. They know what to talk about an orphan, and then which format. We also look at that we can reduce costs internally and for the food, different projects and then on product that we've established, we build credibility within the organization that helped to disseminate the cultural transformation. >>So once others air seeing, seeing the benefits that that captured, they're more likely to to feel good about the cloud work. >>Yeah, that's that's the true and also notes of the news. Things like our teams, they are interesting about that. You see more and more people talking about our driveway and also talk about the UAV's and how can we improve the did he re efficiency and the same time is come back to say that teams think about how to make themselves to be a product owner and the product the way of the great. Let's the glistening for the whole team >>because I want to bring you in here a little bit. So talk to me about how ex Center is helping Novartis, particularly in in this eight of us. Caught initiative. >>Six incher is a leader in business and technical i t transformation programmes. So what we're bringing on the table is in the expertise with not only the technology and the AWS elements, but also the business and technical transformation expertise that have we have over the years in the firm. On additionally, I think you know, it's not only about technology change. As you mentioned, it's all a lot of change and operating model and and also kind of working with a very blended team. Across that expertise and experience is what you bring to the table >>a blended team, culturally, regionally, actually, all of it >>one of that belief. I mean, just to give an example. We are working across steams in roughly about six geography ese from various cultures. Where's countries? And it's it's, ah, various time zones, which makes it quite challenging to make it all work together. So you started the journey. I hope you succeed in it. And, uh, you know, it's working well, so far, >>so Cloud is is really a megatrend right now. What are the differences that you're seeing across Regions, countries, industries? >>So I think it's this many answers many parts of the answer to the question. So I think if I talk about, um, industries So you know, initially when clouds started, we had seen a major up take off the cloud technology and the company that manufactured the clown technology and telecommunications, and you know where the older infrastructure and technology aspects were, Whereas companies like health care and media and metals and mining, We're kind of behind the curve in adoption rates because off their respective, you know, concerns around compliance and security of data. But I think that trends is slowly shifting. US. Companies are becoming more open. I think I've seen how the public cloud has matured. The security models, you know, are speaking for themselves. People can understand the benefits from moving to the cloud in terms off, you know, cost rationalization from producing maintenance costs, focusing their proteins on things that they were not able to divert their attention on. >>The fact we had, I think I will say for me and then where I've seen a Novartis if it is access to innovation. So I think loud offering brings a lot off innovation at happy face. That's one hand and also access to extend our collaboration. So when you're in, you know, inside focus I think the relatives from over there wants to walk and collaborate with you. But when you work on the cloud, everybody goes on the cloud. So that's really a stream manifested ate a collaboration with Nextel Partners. >>So how is that changing the culture of Novartis itself? In terms of there, there are more opportunities to collaborate. And it also is maybe changing the kinds of workers you attract because it is is people who want to be doing that in their day to day. >>Well, if you look at it, um, in the past, I think we used to have our own workforce, and then we tried to do a lot of things with our own workers, but I think he's in the on Monte. Workers are full of us, so we have more and more partnerships being announced, and this publishing, I mean used actually to help the company to in revenge himself. So that's actually on one hand on the other side. As you said, I think that to attract with talents I think you need. You also need to have a different future. But you need also to be able to give them the flexibility to work and do the things they like, and we're in a context and a framework. >>One of the things that we hear about so much at the's technology conference is this buzzword of digital transformation and of artisans obviously embarking on its own digital transformation as well as his journey to the cloud. There happen. They're powering each other, they're accelerating each other. How would you describe what is happening to the industry and to know Vargas with it within this, the pharmaceutical industry? >>Yeah, I think, based on our knowledge, to send the why this may be the first. The company can't be trying to build this kind of enterprise level data and also an Alex platform, and based on that, we will be able to counseling date off the history potato intended date on public date, huh? And the Human Industry Day. Then they tried to help us to produce the better products for the patient the same time it gave also the team a chance as you mentioned before, and the look at former more opportunities and the China to leverage in your technology particles of Kayla. >>It's also changed the way that we work every day. So if you look at it now, um, we won't be virtual assistant. We I think we use machine learning elements politics to be able to talkto you are a cheap piece. We actually monitor clickers, Kyle real time having using common centers. So every single day, I think the use off, digital at work and atom in the physical man thinks. And I think we have seen that the adoptions has increased since we have I ever to launch successful products. And I think >>one of the things which, which I really like about working in the bodies, is also I think there's there's an ambition to drive business value quickly. So you know you take a very agile use case, best approach on things rather than having to wait for very long years of time. Plus, the company kind of encourages a culture which is based on mutual cooperation and sharing knowledge, which is great >>because Novartis is really on the vanguard of companies in terms of how much it's embraced, the cloud and how much it's using it. What do you think? Other companies, pharmaceutical companies, but maybe even in other industries as well could learn from the nerve artists example. >>I think one thing people really shy about is, you know, when they moved to the cloud is the security aspect. I think what people probably had failed to realize in the past that there's been so much developments on security in the public cloud, which has bean key focus areas, something nobody's has taken the challenge and has understood that very well. And I think companies can learn from all the different aspects of security that you know were built into our entire transformation work, starting from ingesting data, the user management to access and all of that thing, so that's kind of one thing. Similarly, compliance related aspects as well, you know, So we've g x p compliance is at the core off how we're building our solution. So I think on dhe, if you understand how we built the rules around compliance. But in architecture, I think couples can learn from that a swell and build that is integral part off your not only technology solution, but the process that goes along with it. >>We started our conversation talking about Novartis and its quest to reimagine medicine. How How do you think that your industry is gonna look 5 10 years from now? I mean, the drug discovery process is slow on purpose. I mean, we need to think of patient health and safety for most. But how do you think it really could change the course of how we treat people? >>If if you look at it is more and more treatment required that actually I used and required data as a service or are being actually process for data. So when I am, when we look at the things the way that the industry is changing, I think the times to develop drugs, yes, takes longer. But I think for your use off the data that you have. I think you can try to reduce I cycle. So one of the objective is to reduce the cycle by one firm. Between that, we could bring the day. Is a new director market in eight years, rescues 12 years Today. The other thing is that way for user's data. You can monitor them patient, and you can recommend it the treatment of 80% off foundation. They don't go in and finish her treatment. So I think if we can show the audience to treatment, then there's a lower risk off the admissions to the season and sickness that they have. >>So it's not even not not just Novartis seeing the value of the date. It's the patients themselves, efficiency >>and the d. A r C as well, right? Because I think if you're if the situation is not six and I think the insurance doesn't have to pay. So I think all the value chances is being comes from >>well, sang Loic, because thank you so much for coming on the Cube. It was a really fascinating segment. Thank you. I'm Rebecca night. Stay tuned for more of the cubes. Live coverage of the Ex Center Executive Summit coming up in just a little bit